ImmunityBio Shares Rise Nearly 1% Overnight After Jim Cramer Endorsement
ImmunityBio shares rose nearly 1% overnight after Jim Cramer called the stock a “very good spec.”
ImmunityBio (IBRX) shares rose nearly 1% overnight heading into Tuesday after CNBC host Jim Cramer called it a “very good spec,” citing a wave of biotech acquisitions as the company advances plans to expand the use of its flagship drug, Anktiva, in bladder cancer.IBRX stock closed Monday down about…